Dr. Yoshida, et al reply

To the Editor: We thank Dr. Kawada1 for his interest in our studies2. Since the landmark RRR study3, the field of biological disease-modifying antirheumatic drug (bDMARD) discontinuation study has expanded tremendously4,5,6. However, as Dr. Kawada pointed out, the design of studies varies widely6, making comparison of studies difficult. One important point that has … Address correspondence to Dr. K. Yoshida, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida{at}mail.harvard.edu